Malaria Clinical Trial
Official title:
The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau
The National Malaria Programme in Guinea-Bissau recommends paracetamol for all children
treated for malaria. We, the investigators of the Bandim Health Project, want to evaluate
whether this treatment has any effect on:
- the well-being of the child;
- the parasite clearance time; and
- the rate of a re-appearance of parasites during 35 days of follow-up.
Children presenting at Bandim Health Centre with malaria will be treated with chloroquine
plus paracetamol or chloroquine plus placebo. Blood samples will be obtained daily for the
first 4 days and then once a week until day 35.
A Cochrane Review was unable to show a superior antipyretic effect of paracetamol compared
with placebo in febrile children. Recent research suggests that the time to parasite
clearance in non-severe malaria is longer in children being given paracetamol. As the costs
associated with the use of paracetamol is not trivial and the risk of adverse effects is not
negligible, we want to evaluate the effects of paracetamol on:
- the well-being of the child;
- the parasite clearance time; and
- the recrudescence rate.
Children presenting at Bandim Health Centre with symptoms of malaria and a malaria film
showing mono-infection with P.falciparum will, following consent to participate, randomly be
allocated to treatment with chloroquine and paracetamol or with chloroquine and placebo.
Blood samples will be obtained daily for the first 4 days. The children will be visited and a
malaria film taken on day 7 and then weekly until day 35. On inclusion and whenever
parasitaemia is detected a capillary blood sample will be taken for PCR analyses to be able
to distinguish re-infection from recrudescence.
During follow-up children are recommended to present at the health centre in case of
persistent fever or any other symptoms. Examination and treatment will be free of charge.
Whenever a child has re-infection sulfadoxine/pyrimethamine will be used for re-treatment
following the recommendation of the National malaria Programme.
After the inclusion of 80 children a preliminary analysis will be performed. If 50% or more
of the children in any of the study arms have reappearing parasitaemia the study will be
terminated.
If the parasite clearance time and especially the recrudescence rate is higher for children
being given paracetamol the current recommendation from the National Malaria Programme should
be reconsidered. If children treated with paracetamol feel better during the acute illness
making it more likely for them to have en adequate intake of food and liquid this benefit
should be considered in the evaluation of the current recommendations.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |